Cypherpunk Technologies Q1 Net Loss of \$77.2M Due to Zcash Decline.
Key Takeaways
- Cypherpunk Technologies increased its Zcash holdings to 314,185.70 ZEC, representing 1.88% of the total circulating supply.
- The company invested $5 million in Zcash Open Development Labs (ZODL), marking its first technology investment outside direct ZEC holdings.
- Cypherpunk reported a net loss of $77.2 million for Q1 2026, primarily due to an $77.6 million unrealized loss on ZEC holdings.
- The price of ZEC declined from $508.09 to $240.47 during the quarter.
- Leap Therapeutics, a subsidiary, received FDA Fast Track designation for sirexatamab in treating DKK1-high metastatic colorectal cancer.
- Weighted average common shares outstanding significantly increased to 168,103,535, indicating potential dilution.
Cypherpunk Technologies Inc. (Nasdaq: CYPH) reported a net loss of $77.2 million for Q1 2026, primarily driven by a $77.6 million unrealized loss on its Zcash (ZEC) treasury holdings. During the quarter, the company significantly increased its ZEC reserves to 314,185.70 ZEC and made a strategic $5 million investment in Zcash Open Development Labs (ZODL), the core developer of the Zcash Network. This marks Cypherpunk's first technology investment beyond direct ZEC holdings.
Zcash Holdings and Strategic Investment
Cypherpunk Technologies expanded its Zcash treasury to 314,185.70 ZEC, which constitutes approximately 1.88% of the total circulating Zcash supply. The average purchase price for these holdings was $337.86 per ZEC. Recent acquisitions included 10,279.30 ZEC for $5 million, purchased at an average price of $486.41 per ZEC.
The $5 million investment in ZODL aligns Cypherpunk with other major investors in the Zcash ecosystem, including a16z, Winklevoss Capital, Coinbase, Paradigm, Chapter One, David Friedberg, and Balaji Srinivasan. This investment represents a strategic diversification into privacy technology development.
To enhance transparency for shareholders, Cypherpunk launched a new investor dashboard on its website, cypherpunk.com. This platform offers direct visibility into key metrics, ZEC holdings, privacy investments, and Zcash network data.
Leap Therapeutics Achievements
Leap Therapeutics, a Cypherpunk subsidiary, achieved several milestones. Sirexatamab, an anti-DKK1 monoclonal antibody, received Fast Track designation from the FDA for treating DKK1-high metastatic colorectal cancer. This designation could accelerate its development and approval pathway.
At AACR 2026, Leap Therapeutics presented a new plasma DKK1 biomarker assay. This assay aims to serve as a companion diagnostic for selecting patients who may benefit most from sirexatamab therapy.
Get the Z-Brief
ZEC price analysis and the best Zcash content. 1-2x per month.
Clinical trial outcomes from the Phase 2 DeFianCe study showed positive results. Sirexatamab demonstrated a statistically significant benefit in overall response rate (ORR: 42% vs. 16%, p=0.003) and overall survival (OS not reached vs. 14.39 months, HR 0.47, p=0.0244) in patients with high DKK1 levels (> 380 pg/ml).
Financial Overview
Cypherpunk Technologies reported a net loss of $77.2 million for Q1 2026, an increase from the $15.4 million loss in Q1 2025. This rise was primarily attributed to unrealized losses on the fair value of its ZEC holdings, which are marked to market at quarter-end.
The price of ZEC experienced a sharp decline during the quarter, moving from $508.09 to $240.47. This volatility resulted in a $77.6 million unrealized loss, directly impacting the company’s earnings and potentially its share value.
Research & Development (R&D) expenses decreased significantly to $0.2 million in Q1 2026, down from $12.9 million in Q1 2025, following the completion of clinical trials. Conversely, General & Administrative (G&A) expenses increased to $4.7 million from $3.0 million, mainly due to higher stock-based compensation for employees and directors.
As of March 31, 2026, the company's cash and cash equivalents totaled $6.7 million. Its ZEC treasury holdings were valued at $73.8 million, based on a ZEC price of $240.47.
Total assets declined from $163.2 million at year-end 2025 to $87.4 million at March 31, 2026. Stockholders’ equity also decreased from $153.5 million to $84.4 million, predominantly due to the unrealized loss on ZEC holdings. The weighted average common shares outstanding increased significantly to 168,103,535 from 41,268,894, indicating a dilution risk for shareholders.
Strategic Risks
Cypherpunk Technologies' financial performance and share price are highly sensitive to ZEC price movements. The company’s share price may exhibit a high correlation to ZEC price due to this sensitivity.
Custody risks are present due to reliance on Gemini Space Station and affiliates for ZEC trading and custody. Regulatory and tax uncertainties surrounding digital assets, competition, and tax treatment could also affect future operations and value creation.
For Leap Therapeutics, risks include challenges in the development and commercialization of sirexatamab, capital requirements, manufacturing capacity, intellectual property protection, and competition from other therapies.